Search research articles
Contact Us
Filters
Showing results (31-40 of 56) with videos related to
Page
of 6
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
January 16, 2008
Deterioration of quality of life of high-risk breast cancer patients treated with high-dose chemotherapy: the PEGASE 01 Quality of Life Study
Patricia Marino, Henri Roché, Pierre Biron, et al.
European Urology
|
November 7, 2006
Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial
Jean-Pierre Droz, Andrew Kramar, Pierre Biron, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
January 17, 2008
Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge
Catherine Sebban, Sophie Dussart, Christine Fuhrmann, et al.
Hematological Oncology
|
February 6, 2014
Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up
Emmanuelle Nicolas-Virelizier, Céline Ségura-Ferlay, Herve Ghesquières, et al.
Bulletin Du Cancer
|
September 13, 2007
[Are antiangiogenic antibodies universal for solid tumor?]
Isabelle Ray-Coquard, Thomas Bachelot, Chadi Saba, et al.
Bulletin Du Cancer
|
June 17, 2006
[Prognostic factors for febrile neutropenia]
Isabelle Ray-Coquard, Christophe Borg, Thomas Bachelot, et al.
Breast Cancer Research and Treatment
|
December 25, 2010
Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994-1998 and 2003-2006
Guillaume Galy, Sana Intidhar Labidi-Galy, David Perol, et al.
BMC Cancer
|
April 21, 2010
Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region
Antoine Lurkin, Francoise Ducimetière, Dominique Ranchère Vince, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 19, 2008
Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP
Stéphane Culine, Andrew Kramar, Christine Théodore, et al.
Applied Health Economics and Health Policy
|
February 26, 2013
Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial
Lionel Perrier, Anne Lefranc, David Pérol, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 56) with videos related to
Sort By:
Page
of 6
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
January 16, 2008
Deterioration of quality of life of high-risk breast cancer patients treated with high-dose chemotherapy: the PEGASE 01 Quality of Life Study
Patricia Marino, Henri Roché, Pierre Biron, et al.
European Urology
|
November 7, 2006
Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial
Jean-Pierre Droz, Andrew Kramar, Pierre Biron, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
January 17, 2008
Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge
Catherine Sebban, Sophie Dussart, Christine Fuhrmann, et al.
Hematological Oncology
|
February 6, 2014
Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up
Emmanuelle Nicolas-Virelizier, Céline Ségura-Ferlay, Herve Ghesquières, et al.
Bulletin Du Cancer
|
September 13, 2007
[Are antiangiogenic antibodies universal for solid tumor?]
Isabelle Ray-Coquard, Thomas Bachelot, Chadi Saba, et al.
Bulletin Du Cancer
|
June 17, 2006
[Prognostic factors for febrile neutropenia]
Isabelle Ray-Coquard, Christophe Borg, Thomas Bachelot, et al.
Breast Cancer Research and Treatment
|
December 25, 2010
Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994-1998 and 2003-2006
Guillaume Galy, Sana Intidhar Labidi-Galy, David Perol, et al.
BMC Cancer
|
April 21, 2010
Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region
Antoine Lurkin, Francoise Ducimetière, Dominique Ranchère Vince, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 19, 2008
Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP
Stéphane Culine, Andrew Kramar, Christine Théodore, et al.
Applied Health Economics and Health Policy
|
February 26, 2013
Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial
Lionel Perrier, Anne Lefranc, David Pérol, et al.
Page
of 6